SynthesisFrontiers in oncology2025
The research perspectives and frontiers on radiotherapy for hepatocellular carcinoma: a bibliometric analysis and systematic review.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Research into radiotherapy(RT) for hepatocellular carcinoma(HCC) has significantly advanced, underscoring its critical role in systemic therapy. However, there remains a notable lack of quantitative and analytical studies specifically addressing RT in the context of HCC. This study aims to evaluate the evolution of RT research and provide a comprehensive analysis of RT studies using bibliometric citation analysis. Methods: A literature search was conducted on July 2, 2024, to extract relevant publications from the Science Citation Index-Expanded(SCIE) of the Web of Science Core Collection(WoSCC), spanning the years 2014 to 2023. Bibliometric and quantitative assessments of the collected publications were performed using visualization tools such as CiteSpace and VOSviewer. Results: The research identified 822 manuscripts authored by 4681 researchers from 1083 institutions across 17 countries, published in 225 journals, and involving 16183 co-cited references from 2282 journals. The United States led in publication volume with 147 articles (17.9%), showing close collaboration with Canada and China. Key areas of focus included the use of RT for HCC with portal vein tumor thrombosis and its combination with transarterial chemoembolization for advanced HCC treatment, which have garnered significant global interest. Recently, particle therapy and the integration of targeted therapies and immunotherapy with RT have emerged as critical themes and frontiers in this research domain. Discussion: This study provides a comprehensive analysis and summary of the current research trends and emerging insights regarding RT in HCC. RT combined with transarterial chemoembolization(TACE) for portal vein tumor thrombosis(PVTT) in HCC has received widespread attention, while particle therapy and combination targeted immunotherapies with RT are essential topics and emerging areas of interest. The resultant synthesis offers a substantive foundation for healthcare practitioners and researchers, providing pivotal meaningful insights that can guide and inspire further research efforts in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.